title: Dopamine D3 and 5-HT1B receptor dysregulation as a result of psychostimulant intake and forced abstinence: Implications for medications development.
abstract: Addiction to psychostimulants, including cocaine and amphetamine, is associated with dysregulation of dopamine and serotonin (5-HT) neurotransmitter systems. Neuroadaptations in these systems vary depending on the stage of the drug taking-abstinence-relapse cycle. Consequently, the effects of potential treatments that target these systems may vary depending on whether they are given during abstinence or relapse. In this review, we discuss evidence that dopamine D3 receptors (D3Rs) and 5-HT1B receptors (5-HT1BRs) are dysregulated in response to both chronic psychostimulant use and subsequent abstinence. We then review findings from preclinical self-administration models which support targeting D3Rs and 5-HT1BRs as potential medications for psychostimulant dependence. Potential side effects of the treatments are discussed and attention is given to studies reporting positive treatment outcomes that depend on: 1) whether testing occurs during self-administration versus abstinence, 2) whether escalation of drug self-administration has occurred, 3) whether the treatments are given repeatedly, and 4) whether social factors influence treatment outcomes. We conclude that D3/D2 agonists may decrease psychostimulant intake; however, side effects of D3/D2R full agonists may limit their therapeutic potential, whereas D3/D2R partial agonists have fewer undesirable side effects. D3-selective antagonists may not reduce psychostimulant intake during relapse, but nonetheless, may decrease motivation for seeking psychostimulants with relatively few side-effects. 5-HT1BR agonists provide a striking example of treatment outcomes that are dependent on the stage of the addiction cycle. Specifically, these agonists initially increase cocaine's reinforcing effects during maintenance of self-administration, but after a period of abstinence they reduce psychostimulant seeking and the resumption of self-administration. In conclusion, we suggest that factors contributing to dysregulation of monoamine systems, including drug history, abstinence, and social context, should be considered when evaluating potential treatments to better model treatment effects in humans. This article is part of a Special Issue entitled 'NIDA 40th Anniversary Issue'.
authors: School of Life Sciences, P.O. Box 874501, Arizona State University, Tempe, AZ 85287-4501, USA. Electronic address: janet.neisewander@asu.edu.
authors: Janet L
authors: JL
authors: Neisewander
authors: Timothy H C
authors: TH
authors: Cheung
authors: Nathan S
authors: NS
authors: Pentkowski
mesh_terms: D000818:Animals; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D006801:Humans; D044302:Receptor, Serotonin, 5-HT1B / Q000378:metabolism*; D050637:Receptors, Dopamine D3 / Q000378:metabolism*; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy / Q000503:physiopathology*
chemical_list: D000697:Central Nervous System Stimulants; D044302:Receptor, Serotonin, 5-HT1B; D050637:Receptors, Dopamine D3
keywords: 5-HT(1B) receptors; 5-HT(1B)Rs; A(2A)Rs; Addiction; Amphetamine; BLA; CeA; Cocaine; D3Rs; EPM; FR; Incentive motivation; NAc; NAcc; NAcsh; OCD; PR; Reinstatement/extinction; SA; Self-administration; VI; VTA; adenosine A(2A) receptors; basolateral amygdala; central amygdala; dSt; dopamine D3 receptors; dorsal striatum; elevated plus maze; fixed ratio; nucleus accumbens; nucleus accumbens core; nucleus accumbens shell; obsessive–compulsive disorder; progressive ratio; self-administration; variable interval; ventral tegmental area
references: Psychopharmacology (Berl). 1999 Nov;147(2):143-52
references: 10591881
references: J Pharmacol Exp Ther. 1998 Oct;287(1):187-97
references: 9765337
references: Psychopharmacology (Berl). 1989;97(1):59-64
references: 2496428
references: Psychopharmacology (Berl). 1996 Mar;124(1-2):2-34
references: 8935797
references: Neuroscience. 2011 Mar 10;176:152-61
references: 21168475
references: Br J Pharmacol. 1993 Dec;110(4):1621-9
references: 8306109
references: Neuropsychopharmacology. 2003 Feb;28(2):329-38
references: 12589386
references: J Neurosci. 2002 Dec 15;22(24):10856-63
references: 12486179
references: J Med Chem. 2005 Jun 2;48(11):3663-79
references: 15916415
references: Psychopharmacology (Berl). 1999 Jan;141(1):99-106
references: 9952071
references: Psychopharmacology (Berl). 2008 Jul;199(1):37-46
references: 18481046
references: CNS Neurol Disord Drug Targets. 2006 Feb;5(1):25-43
references: 16613552
references: Psychopharmacology (Berl). 2008 Nov;201(1):43-53
references: 18612628
references: Bioorg Med Chem. 2005 Jan 3;13(1):77-87
references: 15582454
references: Psychopharmacology (Berl). 2007 Aug;193(2):159-70
references: 17393143
references: Neuroreport. 1997 Jul 7;8(9-10):2373-7
references: 9243643
references: Neuropharmacology. 2009 May-Jun;56(6-7):956-69
references: 19371586
references: Psychopharmacology (Berl). 1998 Dec;140(3):365-70
references: 9877016
references: Biol Psychiatry. 2007 Mar 1;61(5):582-90
references: 16806092
references: J Neurosci. 2002 Nov 1;22(21):9595-603
references: 12417684
references: Synapse. 2011 Aug;65(8):724-32
references: 21132811
references: Br J Pharmacol. 1985 Mar;84(3):743-53
references: 2580582
references: J Neurochem. 2000 Dec;75(6):2415-26
references: 11080193
references: Eur J Neurosci. 2002 Jun;15(12):2016-26
references: 12099907
references: Psychopharmacology (Berl). 2003 Jul;168(1-2):84-98
references: 12721782
references: J Pharmacol Exp Ther. 2008 Feb;324(2):587-99
references: 18024789
references: Pharmacol Biochem Behav. 2002 Apr;71(4):581-7
references: 11888549
references: Psychopharmacology (Berl). 1999 Jan;141(3):326-31
references: 10027515
references: Pharmacol Rev. 2013 Jan 23;65(1):255-90
references: 23343975
references: Neuroreport. 1994 Apr 14;5(8):1005-8
references: 8061279
references: Pharmacol Biochem Behav. 2001 Apr;68(4):701-8
references: 11526967
references: J Cell Sci. 1999 Mar;112 ( Pt 6):967-76
references: 10036246
references: Am J Addict. 2000 Winter;9(1):38-50
references: 10914292
references: Appetite. 2009 Dec;53(3):422-5
references: 19635514
references: Neuropsychopharmacology. 2003 Jan;28(1):163-9
references: 12496953
references: Pharmacol Biochem Behav. 2006 Mar;83(3):403-9
references: 16647107
references: Headache. 2010 Feb;50(2):264-72
references: 19925619
references: Eur J Pharmacol. 2011 Jun 1;659(2-3):187-92
references: 21466803
references: Am J Drug Alcohol Abuse. 1995 Aug;21(3):289-301
references: 7484980
references: Drug Discov Today. 2005 Jul 1;10(13):917-25
references: 15993811
references: Nat Neurosci. 2002 Jul;5(7):625-6
references: 12055635
references: Prog Neuropsychopharmacol Biol Psychiatry. 1983;7(4-6):591-7
references: 6686696
references: Science. 1996 Mar 15;271(5255):1586-9
references: 8599115
references: J Neural Transm (Vienna). 2002 Apr;109(4):513-21
references: 11956970
references: J Pharmacol Exp Ther. 1998 Sep;286(3):1231-8
references: 9732383
references: Int J Neuropsychopharmacol. 2007 Oct;10(5):675-81
references: 16959056
references: J Pharmacol Exp Ther. 2005 Sep;314(3):1248-56
references: 15980060
references: Neuropsychopharmacology. 2003 Jun;28(6):1150-9
references: 12700684
references: Am J Drug Alcohol Abuse. 2008;34(6):721-9
references: 18855244
references: Neuropsychopharmacology. 2006 Jul;31(7):1393-405
references: 16205781
references: Brain Res. 2011 Feb 28;1376:1-9
references: 21172311
references: J Pharmacol Exp Ther. 2000 Sep;294(3):1154-65
references: 10945872
references: J Neurosci. 2012 Jan 25;32(4):1353-9
references: 22279219
references: Addiction. 2000 Aug;95 Suppl 2:S91-117
references: 11002906
references: J Pharmacol Exp Ther. 2004 Nov;311(2):711-9
references: 15226384
references: Neuropsychopharmacology. 2000 Feb;22(2):108-24
references: 10649824
references: Psychopharmacology (Berl). 2003 Jul;168(1-2):3-20
references: 12402102
references: Psychopharmacology (Berl). 2004 Oct;175(4):414-27
references: 15064914
references: Behav Brain Res. 2010 Dec 25;214(2):386-94
references: 20600343
references: Am J Psychiatry. 2007 Jan;164(1):160-2
references: 17202560
references: J Pharmacol Exp Ther. 1995 Sep;274(3):1182-91
references: 7562486
references: Eur J Pharmacol. 2007 Oct 31;572(2-3):171-4
references: 17628535
references: NIDA Res Monogr. 1988;84:25-43
references: 3147384
references: Arch Gen Psychiatry. 1986 Feb;43(2):107-13
references: 3947206
references: Drug Alcohol Depend. 2006 Jan 4;81(1):63-70
references: 16005579
references: J Neurosci. 1996 Oct 1;16(19):6100-6
references: 8815892
references: J Clin Psychiatry. 1988 Feb;49 Suppl:34-8
references: 3257487
references: Psychopharmacology (Berl). 1995 Dec;122(4):351-7
references: 8657832
references: Neuropharmacology. 2007 Feb;52(2):444-9
references: 17059838
references: Neuropsychopharmacology. 1996 Jun;14(6):375-424
references: 8726752
references: Addict Biol. 2007 Jun;12(2):133-51
references: 17508985
references: Psychopharmacology (Berl). 2000 Jul;150(4):422-9
references: 10958084
references: Neuropharmacology. 2012 Dec;63(8):1346-59
references: 22960444
references: Neuroscience. 2006 Oct 13;142(2):451-61
references: 16844308
references: Neurosci Lett. 2003 Nov 20;351(3):169-72
references: 14623133
references: Science. 1998 Oct 9;282(5387):298-300
references: 9765157
references: Behav Pharmacol. 1995 Jun;6(4):333-347
references: 11224342
references: Eur Addict Res. 2004;10(4):147-55
references: 15367815
references: Nat Rev Neurosci. 2004 Jun;5(6):483-94
references: 15152198
references: Psychopharmacology (Berl). 2002 Sep;163(2):142-50
references: 12202960
references: Biol Psychiatry. 2012 Sep 1;72(5):396-404
references: 22541946
references: J Chem Inf Model. 2010 Nov 22;50(11):1970-85
references: 20936866
references: Emerg Med J. 2007 Apr;24(4):e20
references: 17384366
references: Addiction. 2003 Jan;98(1):7-22
references: 12492751
references: J Pharmacol Exp Ther. 1999 Oct;291(1):353-60
references: 10490924
references: J Med Chem. 1990 Aug;33(8):2087-93
references: 2374139
references: Neuropharmacology. 1984 Jun;23(6):655-61
references: 6462374
references: Am J Drug Alcohol Abuse. 2007;33(6):769-76
references: 17994473
references: Pol J Pharmacol. 2002 Jul-Aug;54(4):299-312
references: 12523484
references: Neuropsychopharmacology. 2002 Jan;26(1):18-26
references: 11751029
references: Neuropsychopharmacology. 2011 Apr;36(5):1104-13
references: 21289600
references: Mov Disord. 2011 Jan;26(1):147-52
references: 20818603
references: Pharmacol Biochem Behav. 2005 Feb;80(2):297-307
references: 15680183
references: Am J Addict. 2011 Mar-Apr;20(2):179-80
references: 21314764
references: Psychopharmacology (Berl). 2007 Apr;191(3):759-65
references: 16953383
references: Neuropharmacology. 2004;47 Suppl 1:256-73
references: 15464142
references: J Psychopharmacol. 1998;12(1):23-30
references: 9584965
references: J Neurosci. 1998 Dec 1;18(23):10078-89
references: 9822762
references: J Psychopharmacol. 2012 Sep;26(9):1231-43
references: 21969105
references: Biol Psychiatry. 2002 Jun 1;51(11):896-901
references: 12022963
references: Psychopharmacology (Berl). 1997 Jun;131(3):264-70
references: 9203237
references: Psychopharmacology (Berl). 1999 Apr;143(3):254-60
references: 10353427
references: ACS Chem Neurosci. 2012 Dec 19;3(12):1050-62
references: 23259040
references: Eur J Pharmacol. 2007 Mar 22;559(2-3):165-72
references: 17291490
references: J Med Chem. 2011 Mar 24;54(6):1555-64
references: 21348515
references: Brain Res. 1990 Jan 22;507(2):344-6
references: 2337776
references: J Pharmacol Exp Ther. 2007 May;321(2):573-82
references: 17272677
references: Psychopharmacology (Berl). 1999 Mar;142(4):343-51
references: 10229058
references: Am J Med Genet. 2001 Aug 8;105(6):489-97
references: 11496363
references: Brain Res. 2007 Apr 27;1143:208-20
references: 17320828
references: Behav Pharmacol. 2009 Sep;20(5-6):492-504
references: 19696656
references: J Clin Psychopharmacol. 2008 Oct;28(5):570-2
references: 18794657
references: Addict Biol. 2010 Jul;15(3):312-23
references: 20456290
references: J Pharmacol Exp Ther. 2002 Nov;303(2):791-804
references: 12388666
references: Neuropsychopharmacology. 2001 Nov;25(5):789-92
references: 11682262
references: Biochem Pharmacol. 2012 Oct 1;84(7):882-90
references: 22781742
references: Psychopharmacology (Berl). 2002 Oct;164(1):49-60
references: 12373419
references: Nat Rev Neurosci. 2009 Aug;10(8):561-72
references: 19571793
references: J Consult Clin Psychol. 1993 Dec;61(6):952-65
references: 8113496
references: Behav Pharmacol. 2012 Jun;23(3):280-91
references: 22470105
references: Neuron. 2009 Feb 26;61(4):502-10
references: 19249271
references: Nature. 2001 Jul 12;412(6843):141-2
references: 11449260
references: Nat Neurosci. 2002 Feb;5(2):169-74
references: 11802171
references: J Atten Disord. 2010 Jan;13(4):358-68
references: 19520999
references: Pharmacol Biochem Behav. 2002 Jun;72(3):623-32
references: 12175459
references: Crit Rev Neurobiol. 1996;10(1):101-17
references: 8853956
references: Psychopharmacology (Berl). 2011 Aug;216(3):379-87
references: 21373790
references: Brain Res. 1997 Jun 20;760(1-2):281-6
references: 9237548
references: Pharmacogenet Genomics. 2006 Jan;16(1):25-36
references: 16344719
references: J Neurochem. 1983 Dec;41(6):1769-73
references: 6196446
references: Neuroreport. 1995 Jan 26;6(2):329-32
references: 7756621
references: Brain Res Bull. 2003 Oct 15;61(6):595-601
references: 14519456
references: J Psychopharmacol. 2000;14(4):340-6
references: 11198050
references: Neuropsychopharmacology. 2006 Jul;31(7):1452-61
references: 16205775
references: J Neurosci. 2002 Apr 1;22(7):2977-88
references: 11923462
references: Exp Clin Psychopharmacol. 2012 Oct;20(5):352-63
references: 22867038
references: Pharmacol Biochem Behav. 2008 Jun;89(4):499-507
references: 18329700
references: Neuropsychopharmacology. 1998 Jul;19(1):48-59
references: 9608576
references: CNS Drugs. 2012 Nov;26(11):949-57
references: 23018546
references: Eur J Neurosci. 1998 May;10(5):1676-86
references: 9751140
references: Psychopharmacology (Berl). 2009 Sep;206(1):73-84
references: 19513698
references: Pharmacol Biochem Behav. 2000 May;66(1):129-36
references: 10837852
references: J Clin Psychiatry. 2007 Dec;68(12):1901-6
references: 18162021
references: Psychopharmacology (Berl). 2011 Jun;215(4):609-20
references: 21207013
references: Psychopharmacology (Berl). 1998 Jan;135(2):151-60
references: 9497020
references: J Pharmacol Exp Ther. 2005 Dec;315(3):1278-87
references: 16135699
references: Eur J Pharmacol. 1987 Jul 9;139(2):205-14
references: 2443369
references: Psychopharmacology (Berl). 1996 Nov;128(2):150-60
references: 8956376
references: Alcohol Clin Exp Res. 2009 Sep;33(9):1589-95
references: 19519719
references: Psychopharmacology (Berl). 2003 Mar;166(3):298-305
references: 12589523
references: Trends Pharmacol Sci. 2007 Aug;28(8):390-6
references: 17629962
references: J Pharmacol Exp Ther. 2010 Aug;334(2):556-65
references: 20494958
references: Cell Mol Neurobiol. 1994 Apr;14(2):185-91
references: 7842476
references: Psychopharmacology (Berl). 1997 Aug;132(3):255-60
references: 9292625
references: Pharmacol Rep. 2008 Nov-Dec;60(6):798-810
references: 19211971
references: J Neurosci. 2000 Dec 1;20(23):8677-84
references: 11102473
references: Eur J Pharmacol. 2008 Nov 12;597(1-3):27-33
references: 18831971
references: Behav Neurosci. 2008 Feb;122(1):129-39
references: 18298256
references: Addict Biol. 2012 Mar;17(2):259-73
references: 21507153
references: Exp Clin Psychopharmacol. 2008 Dec;16(6):475-83
references: 19086768
references: J Neurochem. 2006 Dec;99(5):1363-76
references: 17074068
references: Addict Biol. 2009 Sep;14(4):419-30
references: 19650818
references: Drug Alcohol Depend. 2012 Sep 1;125(1-2):173-7
references: 22546848
references: Am J Med Genet B Neuropsychiatr Genet. 2013 Mar;162B(2):169-76
references: 23335468
references: Psychopharmacology (Berl). 2012 Nov;224(1):33-56
references: 22955569
references: Front Behav Neurosci. 2009 Sep 07;3:13
references: 19826615
references: Psychopharmacology (Berl). 1997 Dec;134(3):309-17
references: 9438681
references: Behav Pharmacol. 2012 Aug;23(4):331-8
references: 22785383
references: J Pharmacol Exp Ther. 2007 Jan;320(1):1-13
references: 16803859
references: Behav Pharmacol. 2009 Sep;20(5-6):363-79
references: 19724195
references: Synapse. 2005 Jul;57(1):17-28
references: 15858839
references: Neuropsychopharmacology. 2003 Aug;28(8):1400-11
references: 12784105
references: NIDA Res Monogr. 1988;81:74-80
references: 3136393
references: Psychopharmacology (Berl). 1993;112(2-3):163-82
references: 7871016
references: Behav Pharmacol. 2010 May;21(3):171-81
references: 20463460
references: Pharmacol Biochem Behav. 2009 Aug;93(2):141-7
references: 19426754
references: Neuropsychopharmacology. 2004 Aug;29(8):1479-87
references: 15100700
references: J Pharmacol Exp Ther. 2000 Aug;294(2):680-7
references: 10900248
references: Headache. 2012 Feb;52(2):198-203
references: 22289074
references: Neuroscience. 1994 Jan;58(1):167-82
references: 8159291
references: Psychopharmacology (Berl). 2004 Jul;174(3):341-57
references: 14985929
references: Pharmacol Biochem Behav. 2011 Oct;99(4):634-8
references: 21683731
references: Naunyn Schmiedebergs Arch Pharmacol. 1995 Nov;352(5):583-4
references: 8751090
references: EMBO J. 1991 Dec;10(13):4017-23
references: 1836757
references: Neuropsychopharmacology. 2003 May;28(5):919-31
references: 12637948
references: Nature. 1999 Jul 22;400(6742):371-5
references: 10432116
references: Life Sci. 1987 Aug 3;41(5):635-42
references: 2955189
references: Neuropharmacology. 2009 Mar;56(4):752-60
references: 19136017
references: Behav Pharmacol. 2004 Dec;15(8):523-34
references: 15577451
references: Biol Psychiatry. 2011 Apr 15;69(8):780-7
references: 21353664
references: Eur J Neurosci. 2005 Jun;21(12):3427-38
references: 16026480
references: Psychopharmacology (Berl). 1995 Jul;120(1):10-20
references: 7480530
references: J Med Chem. 2007 Aug 23;50(17):4135-46
references: 17672446
references: J Pharmacol Exp Ther. 2013 Feb;344(2):329-38
references: 23211363
references: Prog Neuropsychopharmacol Biol Psychiatry. 2007 Nov 15;31(8):1593-600
references: 17900777
references: Neuroscience. 1999;88(3):899-915
references: 10363826
references: J Neurosci. 2006 Jun 14;26(24):6583-8
references: 16775146
references: Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17675-80
references: 23045656
references: CNS Neurosci Ther. 2010 Jun;16(3):e18-42
references: 20345970
references: Int J Neuropsychopharmacol. 2007 Apr;10(2):167-81
references: 16426478
references: Psychopharmacology (Berl). 2000 Sep;152(1):74-9
references: 11041318
references: Eur J Clin Pharmacol. 2010 Jan;66(1):5-27
references: 19809810
references: Expert Opin Pharmacother. 2008 Jun;9(9):1451-62
references: 18518777
references: Behav Pharmacol. 2002 Sep;13(5-6):389-96
references: 12394415
references: Eur Neuropsychopharmacol. 2001 Apr;11(2):169-72
references: 11313163
references: Neuropharmacology. 1994 Mar-Apr;33(3-4):367-86
references: 7984275
references: Clin Drug Investig. 2010;30(12):827-841
references: 20923242
references: Psychopharmacology (Berl). 2012 Jan;219(1):123-35
references: 21701814
references: Physiol Behav. 1996 Sep;60(3):933-9
references: 8873272
references: Eur Neuropsychopharmacol. 1998 Dec;8(4):325-8
references: 9928925
references: Biol Psychiatry. 2010 May 1;67(9):800-3
references: 20172504
references: Synapse. 1995 Jan;19(1):18-28
references: 7709340
references: MedGenMed. 2007 Sep 05;9(3):48
references: 18092054
references: Science. 1997 Mar 14;275(5306):1593-9
references: 9054347
references: Nature. 1997 Apr 24;386(6627):830-3
references: 9126741
references: Brain Res Brain Res Rev. 2005 Jul;49(1):77-105
references: 15960988
references: Brain Res Mol Brain Res. 1997 May;45(2):335-9
references: 9149110
references: Neuroscience. 2010 Aug 11;169(1):182-94
references: 20435100
references: Psychopharmacology (Berl). 2009 Dec;207(3):401-11
references: 19779699
references: Biol Psychiatry. 2012 Sep 1;72(5):414-21
references: 22503110
references: Eur J Pharmacol. 1994 Jan 1;266(1):79-85
references: 7907989
references: J Comp Neurol. 2000 Feb 7;417(2):181-94
references: 10660896
references: Trends Pharmacol Sci. 2002 Apr;23(4):151-3
references: 11931978
references: J Psychopharmacol. 2011 Feb;25(2):263-73
references: 20142301
references: Pharmacol Biochem Behav. 1997 Jul;57(3):513-21
references: 9218276
references: J Pharmacol Exp Ther. 1995 Nov;275(2):885-98
references: 7473180
references: Physiol Behav. 2011 Jul 25;104(1):168-72
references: 21557955
references: J Neurosci. 2000 Jan 15;20(2):798-805
references: 10632609
references: Am J Psychiatry. 2005 Aug;162(8):1403-13
references: 16055761
references: J Pharmacol Exp Ther. 2007 Mar;320(3):1268-78
references: 17170312
references: J Pharmacol Exp Ther. 2005 Jul;314(1):310-9
references: 15833897
references: Eur J Pharmacol. 2012 Feb 29;677(1-3):111-5
references: 22227331
references: Psychopharmacology (Berl). 2004 Oct;176(1):57-65
references: 15083257
references: Neuron. 2012 Nov 8;76(3):470-85
references: 23141060
references: J Addict Dis. 1993;12(1):25-35
references: 8381028
references: J Neurochem. 2009 Oct;111(1):217-27
references: 19659573
references: Neurosci Biobehav Rev. 2004 Jan;27(8):739-49
references: 15019424